Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7

Cancer Research

Volumn 58, Issue 10, 1998, Pages 2134-2140

  Piché, Alain ^a   Grim, Jon ^a   Rancourt, Claudine ^a   Gómez Navarro, Jesùs ^a   Reed, John C ^b   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTEIN BCL 2;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032523945     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
2. Hockenbery, D. M., Oltval, Z. N., Yin, X., Milliman, C. L., and Korsmeyer, S. J., Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251, 1993.
3. Yang, E., and Korsmeyer, S. J., Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood, 88: 386-401, 1996.
4. Reed, J. C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol. Clin. N. Am., 9: 451-473, 1995.
5. Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. Involvement of the bcl-2 gene in human follicular lymphoma. Science (Washington DC), 228: 1440-1443, 1985.
6. Krajewski, S., Thor, A. D., Edgerton, S. M., Moore, D. H., Krajewska, M., and Reed, J. C. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin. Cancer Res., 3: 199-208, 1997.
7. Doglioni, C., Dei Tos, A. P., Laurino, L., Chiarelli, C., Barbareschi, M., and Viale, G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates with particular reference to estrogen receptor status. Virchows Arch., 424: 47-51, 1994.
8. Nakasu, S., Nakasu, Y., Nioka, H., Nakajima, M., and Handa, J. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol., 88: 520-526, 1994.
9. Alderson, L. M., Castleberg, R. L., Harsh, G. R., Louis, D. N., and Henson, J. W. Human gliomas with wild-type p53 express bcl-2. Cancer Res., 55: 999-1001, 1995.
10. Bronner, M. P., Culin, C., Reed, J. C., and Furth, E. E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol., 146: 20-26, 1995.
11. Eliopoulos, A. G., Kerr, D. J., Herod, L., Hodgkins, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995.
12. Wang, T. T. Y., and Phang, J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
13. Teixeira, C., Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
14. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
15. Campos, L., Rouault, J. P., Sabido, O. Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P., and Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81: 3091-3096, 1993.
16. Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsma, D. E., Tolcher, A. W., O'Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J, C., and Connors, J. M. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90: 244-251, 1997.
17. Campos, L., Sabido, O., Rouault, J-P., and Guyotat, D. Effects of Bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, 84: 595-600, 1994.
18. Keith, F. J., Bradbury, D. A., Zhu, Y-M., and Russell, H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (Baltimore), 9: 131-138, 1995.
19. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4: 71-79, 1994.
20. Kitada, S., Miyashgita, K., Nishi, S., Tanaka, S., and Reed, J. C. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev., 3: 57-69, 1993.
21. Berchem, G. J., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-736, 1995.
22. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., Mahdi, N. A., Cowell, J. K., and Morgan, G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9: 3049-3055, 1994.
23. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., Stefano, F. D., Ross, P., Corbo, M., and Dziewanowska, Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
24. Duan, L., Bagasra, O., Laughlin, M. A., Oakes, J. W., and Pomerantz, R. J. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc. Natl. Acad: Sci. USA, 91: 5075-5079, 1994.
25. Mhashilkar, A. M., Bagley, J., Chen, S. Y., Szilvay, A. M., heland, D. G., and Marasco, W. A. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J., 14: 1542-1551, 1995.
26. Duan, L., Zhu, M., Bagasra, O., and Pomerantz, R. J. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-Rev single-chain variable fragments. Hum. Gene Ther., 6. 1561-1573, 1995.
27. Levy-Mintz, P., Duan, L., Zhang, H., Hu, B., Dornadula, G., Zhu, M., Kulkosky, J., Bizub-Bender, D., Skalka, A. M., and Pomerantz, R. J. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol., 70: 8821-8832, 1996.
28. Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther., 1: 332-337, 1994.
29. Deshane, J., Siegal, G, P., Alvarez, R. D., Wang, M. H., Feng, M., Cabrera, G., Liu, T., Kay, M., and Curiel, D. T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest., 96: 2980-2989, 1995.
30. Deshane, J., Cabrera, G., Grim, J. E., Siegal, G. P., Pike, J., Alvarez, R, D., and Curiel, D. T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol., 59: 8-14, 1995.
31. Graus-Porta, D., Beerli, R. R., and Hynes, N. E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol., 15: 1182-1191, 1995.
32. Jannot, C. B., Beerli, R. R., Mason, S., Gullick, W. J., and Hynes, N. E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene, 13: 275-282, 1996.
33. Jannot, C. B., and Hynes, N. E. Characterization of scFv-421, a single-chain antibody targeted to p53. Biochem. Biophys. Res. Commun., 230: 242-246, 1997.
34. Reed, J. C., Tanaka, S., Cuddy, M., Cho, D., Smith, J., Kalen, R., Saragovi, H. U., and Torigoe, T. A strategy for generating monoclonal antibodies against recombinant baculoviras-produced proteins: application to the bcl-2 oncoprotein. Anal. Biochem., 205: 70-76, 1992.
35. Simultaneous screening of large numbers of recombinant antibody clones using a colony lift assay. Sci. Tools Pharmacia Biotech, 1: 10-11, 1996.
36. Grim, J. E., Deshane, J., Feng, M., Lieber, A., Kay, M., and Curiel, D. T. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. Am. J. Resp. Cell Mol. Biol., 15: 348-354, 1996.
37. Marasco, W. A. Intrabodies: turning the humoral immun system outside in for intracellular immunization. Gene Ther., 4: 11-15, 1997.
38. Manda, M., and Kumar, R. Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ., 7: 311-318, 1996.
39. O'Reilly, L. O., Huang, D. C. S., and Strasser, A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J., 15: 6979-6990, 1996.
40. Jacobsen, M. D., Weil, M., and Raff, M. C. Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. J. Cell Biol., 133: 1041-1051, 1996.
41. Mothes, W., Heinrich, S. U., Graf, R., Nilsson, I. M., Von Heijne, G., Brunner, S., and Rapoport, T. A. Molecular mechanism of membrane protein integration into the endoplasmic reticulum. Cell, 89: 523-533, 1997.
42. Barnes, M. N., Deshane, J. S., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin. Cancer Res., 2: 1089-1095, 1996.